BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 11438644)

  • 21. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication.
    Furstenthal L; Kaiser BK; Swanson C; Jackson PK
    J Cell Biol; 2001 Mar; 152(6):1267-78. PubMed ID: 11257126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
    Gong J; Ammanamanchi S; Ko TC; Brattain MG
    Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
    Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PKCeta associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes.
    Kashiwagi M; Ohba M; Watanabe H; Ishino K; Kasahara K; Sanai Y; Taya Y; Kuroki T
    Oncogene; 2000 Dec; 19(54):6334-41. PubMed ID: 11175348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The N-terminal domains of cyclin-dependent kinase inhibitory proteins block the phosphorylation of cdk2/Cyclin E by the CDK-activating kinase.
    Rank KB; Evans DB; Sharma SK
    Biochem Biophys Res Commun; 2000 May; 271(2):469-73. PubMed ID: 10799321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limiting amounts of p27Kip1 correlates with constitutive activation of cyclin E-CDK2 complex in HTLV-I-transformed T-cells.
    Cereseto A; Washington Parks R; Rivadeneira E; Franchini G
    Oncogene; 1999 Apr; 18(15):2441-50. PubMed ID: 10229195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
    Orend G; Hunter T; Ruoslahti E
    Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
    Coppock DL; Buffolino P; Kopman C; Nathanson L
    Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.
    Goubin F; Ducommun B
    Oncogene; 1995 Jun; 10(12):2281-7. PubMed ID: 7784076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver.
    Lindeman B; Skarpen E; Oksvold MP; Huitfeldt HS
    Mol Carcinog; 2000 Mar; 27(3):190-9. PubMed ID: 10708481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperoxia induces S-phase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells.
    Bilodeau JF; Faure R; Piedboeuf B; Mirault ME
    Exp Cell Res; 2000 May; 256(2):347-57. PubMed ID: 10772807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
    Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
    Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cell cycle inhibitor p21CIP is phosphorylated by cyclin A-CDK2 complexes.
    Jaumot M; Estañol JM; Casanovas O; Graña X; Agell N; Bachs O
    Biochem Biophys Res Commun; 1997 Dec; 241(2):434-8. PubMed ID: 9425288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.
    Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM
    Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit.
    Gu Y; Turck CW; Morgan DO
    Nature; 1993 Dec; 366(6456):707-10. PubMed ID: 8259216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase.
    Ono T; Kitaura H; Ugai H; Murata T; Yokoyama KK; Iguchi-Ariga SM; Ariga H
    J Biol Chem; 2000 Oct; 275(40):31145-54. PubMed ID: 10878006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop.
    Garrett S; Barton WA; Knights R; Jin P; Morgan DO; Fisher RP
    Mol Cell Biol; 2001 Jan; 21(1):88-99. PubMed ID: 11113184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cyclin E/Cdk2 substrate and Cajal body component p220(NPAT) activates histone transcription through a novel LisH-like domain.
    Wei Y; Jin J; Harper JW
    Mol Cell Biol; 2003 May; 23(10):3669-80. PubMed ID: 12724424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells.
    Cipriano SC; Chen YQ
    Oncogene; 1998 Sep; 17(12):1549-56. PubMed ID: 9794232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
    Park US; Park SK; Lee YI; Park JG; Lee YI
    Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.